Morningstar

Moleculin Biotech Inc MBRX

Stock XNAS

News

Moleculin Releases Next CEO Corner Segment Highlighting Recent Progress in Annamycin MIRACLE Trial

GlobeNewswire Oct 20, 2026, 12:12:00 PM
Moleculin Announces Reverse Stock Split

GlobeNewswire Oct 16, 2026, 1:20:00 PM
Moleculin Biotech to Participate in Advances in Oncology Panel at the 2026 Maxim Growth Summit

GlobeNewswire Oct 7, 2026, 12:45:00 PM
Moleculin Biotech Completes Enrollment in Part A of Phase 2/3 R/R AML MIRACLE Trial, Keeping Program on Track for Q1 2027 Data Readout

GlobeNewswire Sep 29, 2026, 12:45:00 PM
Moleculin Announces Publication of Peer-Reviewed Cardiac Safety Analysis of Annamycin in Frontiers in Cardiovascular Medicine

GlobeNewswire Sep 28, 2026, 11:00:00 AM
Annamycin Turns “Cold” Pancreatic Tumors “Hot” in New Preclinical Data Presented at AACR

GlobeNewswire Sep 25, 2026, 5:05:00 PM
Moleculin Biotech Secures Mexican Patent Protecting Lung-Targeted Liposomal Annamycin Through 2040

GlobeNewswire Sep 23, 2026, 12:25:00 PM
Moleculin to Showcase New Annamycin Data at AACR Conference on Pancreatic Cancer and Two European Scientific Meetings

GlobeNewswire Sep 14, 2026, 12:35:00 PM
Moleculin Presentation from H.C. Wainwright Conference Now Available On-Demand

GlobeNewswire Sep 11, 2026, 12:30:00 PM
Moleculin CEO, Walter Klemp, Participates in the Virtual Investor “Why Now” On-Demand Conference

GlobeNewswire Aug 27, 2026, 1:01:00 PM
Moleculin Biotech Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of Pivotal MIRACLE Trial

GlobeNewswire Aug 14, 2026, 12:30:00 PM
Moleculin Announces Pricing of $9.3 Million Public Offering

GlobeNewswire Jul 31, 2026, 2:12:00 PM
Moleculin’s MIRACLE R/R AML Trial Reports Positive Interim Data with 37% Blinded CRc in Venetoclax-Failed Patients

GlobeNewswire Jul 31, 2026, 12:10:00 PM

Sponsor Center

Transparency is our policy. Learn how it impacts everything we do

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

How we make money

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your personal data

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

Verify your identity, personalize the content you receive, or create and administer your account.
Provide specific products and services to you, such as portfolio management or data aggregation.
Develop and improve features of our offerings.
Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

How we approach editorial content

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.

© Copyright 2026 Morningstar, Inc. All rights reserved. Dow Jones Industrial Average, S&P 500, Nasdaq, and Morningstar Index (Market Barometer) quotes are real-time.